herbal medicine
Ita Wegman (22 February 1876 – 4 March 1943) was born 150 years ago today. Together with Rudolf Steiner, she was a central figure in the development of anthroposophic medicine, an approach that interprets illness through spiritual–cosmological concepts. In 1921, Wegman founded the Klinisch-Therapeutisches Institut in Arlesheim, Switzerland—today the Ita Wegman Clinic—the first hospital dedicated to anthroposophic medicine. Practices developed there included rhythmical massage, a gentle bodywork technique intended to “harmonize” physiological rhythms, and mistletoe-based cancer therapy derived from Viscum album, later marketed as Iscador, as well as many other remedies influences by homeopathy. Wegman also co-founded Weleda, which remains a major producer of anthroposophic remedies and cosmetics.
Despite its continued use in parts of Europe, mistletoe therapy (including Iscador) has not demonstrated reliable clinical efficacy in improving cancer survival or tumor outcomes in well-controlled trials. Major systematic reviews conclude that evidence for benefit is inconsistent, methodologically weak, and often biased, with any reported improvements largely limited to subjective quality-of-life measures. It is therefore regarded by mainstream oncology as an unproven therapy rather than an evidence-based treatment. For Wegman’s other therapeutic innovations the evidence is even less convincing.
Her collaboration with Steiner was both professionally formative and personally intense. They met in the early 1900s, and Wegman later credited Steiner with inspiring her decision to pursue medicine relatively late, enrolling at the University of Zurich. From 1919 onward, their cooperation deepened: Steiner supplied esoteric frameworks derived from anthroposophy, while Wegman sought to translate these ideas into clinical practice. Their collaboration culminated in the book “Fundamentals of Therapy” (1925), published shortly after Steiner’s death.
Speculation about a romantic relationship between Wegman and Steiner has persisted for decades. Purported “love letters” dated to 1924 describe expressions of affection, but most scholars regard them as forgeries, citing factual errors, the absence of originals from Steiner archives, and stylistic inconsistencies with Steiner’s documented correspondence. Steiner himself described their bond in karmic terms, claiming a debt from a past incarnation that explained their closeness despite his marriage to Marie von Sivers. Historian Peter Selg and others interpret the relationship as an intense spiritual and intellectual partnership rather than a conventional affair, though contemporaries did circulate rumors.
Steiner died on March 30, 1925, after a prolonged illness. The exact cause remains uncertain and not definitively confirmed as stomach cancer. Wegman provided Steiner’s main care from September 1924 until his death, leaving her clinic to nurse him in his studio at the Goetheanum in Dornach, Switzerland. She is said to have employed anthroposophic approaches, but specific treatments remain sparsely documented in available accounts.
Following Steiner’s death, Wegman’s authority within the movement became increasingly contested. In 1935 she was expelled from the Anthroposophical Society amid internal power struggles and accusations of doctrinal deviation; this expulsion was formally reversed in 2018. Wegman’s political stance during the Nazi period remains controversial. While anthroposophy as a movement was partially suppressed in Nazi Germany, several leading anthroposophists – including Wegman – sought accommodation rather than resistance. Wegman expressed hopes in the early 1930s that National Socialism might support a spiritual renewal of society and did not publicly oppose the regime. Although she was not a member of the Nazi Party and later faced restrictions, her posture is best described as opportunistic accommodation and ideological ambiguity.
Wegman’s collaboration with Steiner created the foundations of anthroposophic medicine. It also generated enduring scientific, ethical, and political controversies – particularly regarding the medical validity of its treatments and its leaders’ responses to authoritarian power after Steiner’s death.
Psoriasis is an immune-mediated inflammatory skin disease. By more than a decade of clinical validation, Jueyin granules (JYG) have demonstrated multi-target synergistic immunomodulatory and anti-inflammatory effects, offering a characteristic Traditional Chinese Medicine (TCM) therapeutic approach for psoriasis.
Aim of this study was to assess the efficacy and safety of oral JYG in treating psoriasis with blood-heat syndrome. Participants with body surface area (BSA) score less than 10 were allocated to receive JYG or placebo treatment in a 1:1 ratio through central area division and block randomization. The primary outcome is reduction of the psoriasis area severity index (PASI) score and proportion of participants achieving a greater than 50 % reduction in PASI scores (PASI50) at week 8.
Between November 2019 and April 2022, 195 participants were randomly assigned to receive JYG (n = 99) or a placebo (n = 96) at five centers. The JYG group demonstrated significantly greater reductions in PASI and BSA scores than the placebo group at week 8 (both P < 0.001) and maintained these improvements at week 16 (P < 0.001 and P = 0.005, respectively). By week 8, 51.09 % of participants in the JYG group achieved PASI50, compared to 20.65 % in the placebo group (P < 0.001). However, there were no statistical differences in dermatology life quality index (DLQI), visual analog scale (VAS) scores, or relapse rate.
The authors concluded that this study provides conclusive evidence that JYG is a safe and effective treatment for patients with mild-to-moderate psoriasis. The current findings support its use as a complementary and alternative therapy for psoriasis.
I think this paper needs a few explanations:
- What are Jueyin granules? This is a formula consisting of eight Chinese herbs (Haliotis diversicolor, Flos Lonicerae Japonicae, Radix Rehmanniae exsiccate, cortex moutan, Herba Hedyotisdiffusae, Folium isatidis, Smilax china L. and Radix Curcumae)
- What is the history? The formula was developed in the 1950s by Han Xia, a Chinese surgeon, and have been used to treat psoriasis for over 50 years by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine.
- How did he develop it? We don’t know.
- Is the formula available outside China? No, not to the best of my knowledge.
- How reliable is this new trial? As we have discussed repeatedly on this blog, there are good reasons to mistrust Chinese studies.
- If we accept the findings nonetheless, are the conclusions valid? No! Firstly, this study cannot establish the safety of the formula. Secondly, a single trial cannot ‘conclusively’ establish the effectiveness of a therapy.
- Why does a respected journal publish such a dubious study? SERACH ME!
This case report details the death of a 59-year-old woman who succumbed to complications from lead poisoning (cerebral edema and encephalopathy) following the use of an herbal cream to treat hemorrhoids.
The patient with a past medical history of prediabetes was admitted to the emergency department after her husband found her experiencing seizure-like activity that morning. She had been in normal health the previous night, but suffered another seizure in the emergency department that lasted about three minutes and was subsequently started on Levetiracetam. During her most recent physical exam one week ago, her lab workup prompted a follow-up with
hematology due to anemia of unknown etiology. This time, her laboratory results indicated an elevated lactate level of 9.3 mmol/L, and her urine drug screen was negative. Additional labs showed elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALKP) while her complete blood count still showed signs of anemia.
During her hospital stay, the patient developed neurogenic shock and diabetes insipidus. On the fourth day, a serum lead level drawn on the second day returned, showing a level greater than 200 µg/dL Physicians considered various potential sources of her lead exposure, including environmental or occupational contact, accidental ingestion or inhalation of lead particles, unregulated imported cosmetics, or contaminated herbal supplements.
After asking about her use of herbal medications, suspicion arose around a hemorrhoid ointment that the patient had recently purchased from Vietnam through a Facebook advertisement. Consequently, chelation therapy with oral succimer and a continuous infusion of ethylenediaminetetraacetic acid
was immediately initiated.
Cao Bôi Trĩ Cây Thầu Dầu (Castor Oil Hemorrhoid Extract) was promoted for the treatment of hemorrhoids via intra-rectal application . Testing by the California Department of Public Health (CDPH) revealed that the hemorrhoid ointment contained 4% lead (39,000 ppm), a highly lethal concentration. Even minimal lead exposure can be harmful and potentially lead to illness or death; thus, it is advised to avoid products likely to contain lead, especially imported items from other countries with inadequate lead testing standards.
As the patient’s condition continued to deteriorate, concerns for brain death arose. After being informed, the patient’s family consented to proceed with brain death testing. A second exam and a nuclear medicine (NM) brain perfusion scan were completed on the eighth day and it shows the absence of brain perfusion. Despite aggressive management, including seizure control, treatment of cerebral edema, and chelation for severe lead poisoning, the patient passed away on the eighth day due to acute neurological complications from severe lead toxicity complicated by cerebral edema.
As we have often discussed, so-called alternative medicines (SCAMs) can often be contaminated with harmful substances including heavy metals such as lead, e.g.:
- Heavy metal poisoning as a result of using Ayurvedic remedies
- If you ask me, Chinese herbal medicines are best avoided
- Death by homeopathy
- Inadequate regulation of Kratom supplements put consumers at risk
- Another death by homeopathy
- Ayurvedic medicines to die for
- Lead and arsenic intoxications due to ‘natural health products’
- How safe are herbal medicines?
- Ayurvedic medicines: efficacy doubtful with considerable risks
- Contamination and adulteration of herbal remedies
- Another death caused by ‘traditional wisdom’
This case underscores the urgent need for stricter regulations and oversight in the herbal medicine industry to prevent such health hazards. Implementing stronger regulatory measures is essential to ensure that all medicinal and cosmetic products are free from harmful contaminants and to safeguard public health against the significant risks associated with SCAMs.
In the UK, honours for so-called alternative medicine (SCAM) are relatively rare and unsurprisingly controversial. Recently, I reported that Robin Daly, has been awarded an MBE in recognition of his outstanding contributions to the field of integrative cancer care and his tireless work through ‘Yes to Life’.
Since the 2026 New Year’s honours list is just out, I thought it would be interesting to see who else has been given a ‘gong’.
There seems to be nobody in the current list – so, let’s see who in the realm of SCAM has been honoured previously. Here is what I found:
Christina Cunliffe received an OBE in the 2025 ‘King’s Birthday Honours List’ for her 25-year career in developing chiropractic education in the UK and internationally.
Richard Brown got an MBE in 2021 for services to disability and a Lifetime Achievement Award in 2025 for his global impact on the chiropractic profession.
The late George Lewith was given a CBE in 2017 for “Services to Health Research and Complementary Medicine.”
Michael Dixon was honoured twice (2015 and 2024) for his personal service to the Royal Family and his work with the College of Medicine promoting holistic care.
Peter Fisher received an CVO in 2018 for personal service to the Queen as her homeopathic physician.
Christopher Hedley received an MBE in 2015 for services to the profession of herbalists and herbal education.
Simon Fielding was awarded his OBE in the 1998 for his services to osteopathy.
As we see several of these people have also received another honour: they are in my ‘ALTERNATIVE MEDICINE HALL OF FAME’!
Coincidence?
Who knows?!
The above list is surprisingly short, and I am almost certain that it is woefully incomplete. Since it would be nice to have a more complete list, I ask my readers to name other SCAM professionals who have received a gong in the past.
In my last post, I claimed that the evidence for saffron was surprisingly positive. This statement demands further explanations. Saffron contains crocetin, an aglycone of crocin naturally occurring in saffron. Crocetin is said to have a wide range of effects, e.g. cardioprotective, hepatoprotective, neuroprotective, antidepressant, antiviral, anticancer, atherosclerotic, antidiabetic, and memory-enhancing properties. The more important question, thowever, is this:
How good is the clinical evidence?
Here are a few recent systematic reviews on the subject:
Meta-analysis of 8 studies assessing depression outcomes revealed a nonsignificant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10l 95% CI: -0.09 to 0.29). Four studies reporting anxiety outcomes showed a nonsignificant difference between saffron and SSRIs in reducing anxiety symptoms (SMD = 0.04; 95% CI: -0.22 to 0.29). With regard to safety, participants receiving saffron had fewer adverse events than the SSRI group (risk difference: -0.06; 95% CI: -0.09, -0.04; I2: 0%). Conclusion: Saffron could be a potential SSRI alternative to reduce depressive and anxiety symptoms with fewer adverse events. Further research with larger sample sizes and in diverse populations is warranted to validate these findings and explore potential moderators of treatment response.
PREMENSTRUAL SYNDROME AND DYSMENORRHEA (2025)
saffron had a significant positive effect on the symptoms of PMS in women (standardized mean difference [SMD], -0.64; 95% confidence interval [CI], -0.84 to -0.44). Furthermore, saffron was effective in reducing dysmenorrhea (SMD, -0.51; 95% CI, -1.01 to -0.01. Conclusion: saffron exerts beneficial effects on the symptoms of both PMS and dysmenorrhea in women.
Four studies met the inclusion criteria with a total of 118 patients. The results suggested an efficient role of saffron as either an adjuvant therapy to MPH or a single therapy against ADHD, without significant safety issues. Conclusion: Saffron demonstrates promise in improving ADHD symptoms, with an acceptable safety profile. Future well-designed multicentral studies are suggested.
NEUROLOGICAL/PSYCHIATRIC DISORDERS (2024)
Forty-six RCTs were enrolled, and the duration of these trials ranged from 4 to 48 weeks with saffron or its extracts, both alone or in combination with conventional drugs. Saffron was more effective than placebo in improving cognition, depression with an overall effect size of -4.26 (95% CI: -5.76, -2.77), anxiety of -3.75 (95% CI: -5.83, -1.67), and sleep disorders of -1.91 (95% CI: -2.88, -0.93). Conclusion: Saffron was non-inferior to conventional drugs for treating cognitive disorders, depression, anxiety, ADHD, and OCD, and it exhibited good tolerance with few side effects. Saffron may exert protective roles for neurological and psychiatric disorders and represents a relatively favorable and safe treatment.
ten RCTs were included in the systematic review and meta-analysis. A total of 562 participants were enrolled, with 292 assigned to the intervention group and 270 to the control group. Saffron was administered at a dose of 5 mg/day to 1 g/day. Compared with placebo, saffron supplementation significantly reduced FPG (WMD = -8.42 mg/dL; 95% CI: -13.37, -3.47; p = 0.001) and HbA1c (WMD = -0.22%; 95% CI: -0.33, -0.10; p < 0.001). However, there was no significant effect on insulin levels, QUICKI and HOMA-IR. Conclusion: Saffron is effective for patients with diabetes in terms of FPG and HbA1c, therefore, it appears to be a promising adjuvant for the glycemic control of DM. However, the overall methodological quality of the identified studies is heterogeneous, limiting the interpretation of the benefit of saffron in diabetes. More long-term follow-up, well-designed and large-scale clinical trials are warranted to draw definitive conclusions.
FEMALE REPRODUCTIVE SYSTEM DISORDERS (2024)
A total of 50 studies conducted on the effect of C. sativus on the female reproductive system were acquired. These studies confirmed the efficacy of C. sativus or its main phytochemical ingredients in several aspects of the female reproductive system, including regulation of sex hormones, folliculogenesis, ovulation, and protection of the ovary and uterus against several oxidative stress. Several retrieved studies indicated that this herb also can alleviate the symptoms of patients suffering from dysmenorrhea, premenstrual syndrome, menopause, polycystic ovary disease (PCOD), and sexual dysfunction. Furthermore, it is a promising candidate for future studies or even trials regarding ovarian and cervical cancers. cONCLUSION: C. sativus can improve the symptoms of several female reproductive system disorders, which is particularly due to the presence of phytochemical ingredients, such as crocin, crocetin, and safranal.
Eight articles were included, involving 431 participants. Crocus sativus reduced insomnia severity (SMD: 0.53; 95%CI: -0.05 to 1.11; I2 statistic = 59%; p = 0.08) and increased sleep quality (SMD 0.89, 95% CI 0.10 to 1.68; I2 statistic = 90%; p = 0.03; 6 studies, 308 participants, very low-quality evidence) and duration (SMD: 0.57; 95%CI: 0.21 to 0.93; I2 statistic = 40%; p = 0.002; 5 studies; 220 participants, moderate-quality evidence) compared with the placebos. Conclusion: Although there is limited evidence of a very low- to moderate-quality, Crocus sativus may benefit people with insomnia. This non-pharmacological intervention may reduce the chance of adults with insomnia taking sedative-hypnotic medication, thus reducing dependency and withdrawal symptoms.
20 articles met the criteria for analysis. Of the 20 articles, 3 were in-vitro studies, 13 were animal studies, and 4 were human studies. Conclusion: The findings of this systematic study (Except for two studies) suggest that saffron supplementation with potential anti-inflammatory properties may reduce the expression of the inflammatory pathway and the production of inflammatory products in diabetes.
Nine RCTs were included in the meta-analysis, and their quality was assessed using the Cochrane risk of bias tool. The pooled analysis showed that saffron supplementation had no significant effect on serum urea concentrations (WMD: – 1.05 mg/dl; 95% CI – 5.1 to 3; P = 0.6, I2 = 93%, P < 0.001) and serum creatinine levels (WMD: – 0.006 mg/dl; 95% CI – 0.08 to 0.06; P = 0.8, I2 = 79%, P < 0.001) when compared to the placebo group. In the dose-response analysis, we observed a significant non-linear relationship between the duration of saffron supplementation and serum urea and creatinine levels. Conclusions: Saffron supplementation had no significant effect on renal function markers, including urea and creatinine. However, further trials are required to determine the actual effect and safety of saffron intervention in human studies.
CARDIOVASCULAR RISK FACTORS (2022)
32 studies were taken into account (n = 1674). Consumption of saffron significantly decreased triglyceride (TG) (WMD = -8.81 mg/dl, 95%CI: -14.33, -3.28; P = 0.002), total cholesterol (TC) (WMD = -6.87 mg/dl, 95%CI: -11.19, -2.56; P = 0.002), low density lipoprotein (LDL) (WMD = -6.71 mg/dl, 95%CI: -10.51, -2.91; P = 0.001), (P = 0.660), fasting blood glucose (FBG) level (WMD = -7.59 mg/dl, 95%CI: -11.88, -3.30; P = 0.001), HbA1c (WMD = -0.18%, 95%CI: -0.21, -0.07; P < 0.001), homeostasis model assessment-insulin resistance (HOMA-IR) (WMD = -0.49, 95%CI: -0.89, -0.09; P = 0.016), systolic blood pressure (SBP) (WMD = -3.42 mmHg, 95%CI: -5.80, -1.04; P = 0.005), tumor necrosis factor α (TNF-α) (WMD = -2.54 pg/ml, 95%CI: -4.43, -0.65; P = 0.008), waist circumference (WC) (WMD = -1.50 cm; 95%CI: -2.83, -0.18; P = 0.026), malondialdehyde (MDA) (WMD = -1.50 uM/L, 95%CI: -2.42, -0.57; P = 0.001), and alanine transferase (ALT) (WMD = -2.16 U/L, 95%CI: -4.10, -0.23; P = 0.028). Also, we observed that saffron had an increasing effect on total antioxidant capacity (TAC) (WMD = 0.07 mM/L, 95%CI: 0.01, 0.13; P = 0.032). There was linear regression between FBG and the duration of saffron intake. Additionally, the non-linear dose-response analysis has shown a significant association of saffron intervention with HDL (P = 0.049), HOMA-IR (P = 0.002), weight (P = 0.036), ALP (P = 0.016), FBG (P = 0.011), HbA1c (P = 0.002), and TNF-α (P = 0.042). A non-linear association between the length of the intervention and the level of HDL and DBP was also found. Conclusion: saffron could effectively improve TG, TC, LDL, FBG, HbA1c, HOMA-IR, SBP, CRP, TNF-α, WC, MDA, TAC, and ALT.
Eight studies (n = 463 participants) were included in the systematic review. The saffron intake was associated with a statistically significant decrease in aspartate aminotransferase (AST) (SMD: -0.18; 95% CI: -0.34, -0.02; I2 = 0%) in comparison to placebo intake. Our results also indicated that saffron consumption did not have a significant effect on alanine aminotransferase (ALT) (SMD: -0.14; 95% CI: -0.36, 0.09; I2 = 47.0%) and alkaline phosphatase (ALP) levels (SMD: 0.14; 95% CI: -0.18, 0.46; I2 = 42.9%) compared to placebo. Conclusions: Saffron intake showed beneficial impacts on circulating AST levels. However, larger well-designed RCTs are still needed to clarify the effect of saffron intake on these and other liver enzymes.
Eight RCTs were eligible. Saffron supplementation resulted in a significant decrease in systolic blood pressure (weighted mean difference (WMD): -0.65 mmHg; 95% CI: -1.12 to -0.18, p = 0.006) and diastolic blood pressure (DBP) (WMD: -1.23 mmHg; 95% CI: -1.64 to -0.81, p < 0.001). Moreover, saffron supplementation reduced DBP in a non-linear fashion, based on duration (r = -2.45, p-nonlinearity = 0.008). Conclusion: Saffron supplementation may significantly improve both systolic and diastolic blood pressure in adults. It should be noted that the hypotensive effects of saffron supplementation were small and may not reach clinical importance.
COGNITIVE IMPAIRMENT/DEMENTIA (2020)
A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. Conclusions: Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety.
BODY WEIGHT/LIPID PROFILE (2019)
We identified and analyzed 14 eligible studies in this meta-analysis. Our study found a significant reduction in cholesterol and TG following saffron intervention (weighted mean difference [WMD]: -6.36 mg/dl, 95% confidence interval, CI, [-10.58, -2.18] and WMD: -5.37 mg/dl, 95% CI [-10.25, -0.48], respectively). There was no significant effect on weight and LDL concentration. A meta-regression analysis showed that long-term saffron intervention can increase the high-density lipoprotein (HDL) levels. conclusion: findings indicate some benefits of saffron on cholesterol, HDL, and TG compared with placebo. However, we recommend the conduct of adequately powered, high-quality RCTs with short- and long-term follow-up, evaluating relevant clinical outcomes to allow for making definitive recommendations.
A total of 5 studies comprising 173 participants were included in this systematic review and meta-analysis. The analysis showed a statistically significant positive effect of saffron on sexual dysfunction (Std diff in means=0.811; 95% CI, 0.356-1.265) and its subscales (Std diff in means=0.493; 95% CI, 0.261-0.724). Heterogeneity indexes such as Cochran Q index and indicated a heterogeneity among the included studies (Q=9:981, df:4, (p=0.041), I2=59.92%). There was no evidence of publication bias in these studies. Conclusion: saffron was proven effective in improving sexual dysfunction and its subscales among participants; this effect was different on different dimensions of sexual dysfunction. Further studies are required to extend these initial findings.
A total of six trials was ultimately included. All statistical analyses were done by Comprehensive Meta-analysis (CMA) Version 2. Only in one study conducted on sperm parameters, the mean percentage of sperm with normal morphology (p<0.001) and sperm motility (p<0.001) were increased. Quantitative analysis showed that saffron had a significantly positive effect on all dimensions of Erectile Function questionnaire (MD for Erectile function=5.36(p=0.00), Orgasmic function=1.12 (p=0.007), Overall satisfaction=1.23 (p=0.005), Satisfaction with intercourse=2.18 (p=0.00) and Sexual desire=0.78 (p=0.00), Fixed effects model using 3 trials). The result of subgroup analysis based on dimensions of Erectile Function questionnaire showed statistically significant differences among subgroups (p=0.00). Conclusion: saffron has a positive effect on erectile dysfunction. However, our study showed contradictory results about semen parameters. So, interpretation of results is limited because of methodological flaws of the included studies, erectile dysfunction status and a large heterogeneity among them. Further trials are still needed to confirm the current findings.
Twelve studies met THE inclusion criteria. These studies examined the effects of saffron on psychological/behavioral outcomes of: major depressive disorder (n=6), premenstrual syndrome (n = 1), sexual dysfunction and infertility (n=4), and weight loss/snacking behaviors (n=1). The data from these studies support the efficacy of saffron as compared to placebo in improving the following conditions: depressive symptoms (compared to anti-depressants and placebo), premenstrual symptoms, and sexual dysfunction. In addition, saffron use was also effective in reducing excessive snacking behavior. Conclusion: saffron may improve the symptoms and the effects of depression, premenstrual syndrome, sexual dysfunction and infertility, and excessive snacking behaviors. Larger multi-site clinical trials are needed to extend these preliminary findings.
Six studies were identified. In the placebo-comparison trials, saffron had large treatment effects and, when compared with antidepressant medications, had similar antidepressant efficacy. Saffron’s antidepressant effects potentially are due to its serotonergic, antioxidant, anti-inflammatory, neuro-endocrine and neuroprotective effects. Concusion: Research conducted so far provides initial support for the use of saffron for the treatment of mild-to-moderate depression. Further research is required to expand our understanding of the role and actions of saffron in major depression.
___________________________
Collectively, these systematic reviews render saffron unquestionably an interesting herbal remedy. Of course, not all the primary studies are of the highest standard, and neither all all the systematic reviews. But still, for once, I am impressed!
A wonder drug?
No!
But one that deserves our attention.
Saffron, the stigmas of Crocus sativus L., has been used extensively in traditional herbal medicine. Since several years, the research interest in this plant is intense. Thus numerous clinical trials of saffron supplements (in contrast to the spice, supplements are affordable [they use different parts of the plant]) have been published. Almost all of them yield positive results (this invariably makes me suspicious!).
The purpose of this 2-arm, 12-wk, parallel-group, randomized, double-blind, placebo-controlled trial was to examine the effects of supplementation with a saffron extract (Affron) on mood and sleep in adults experiencing subclinical depressive symptoms. 202 adults aged 18-70 with depressive symptoms were supplemented with either 28 mg saffron daily or a placebo. Outcome measures included the Depression, Anxiety, and Stress Scale – 21, Sleep Disturbance and Sleep-Related Impairment Scale, World Health Organization-Five Well-Being Scale, and daily depression, stress, and anxiety ratings.
On the primary outcome measure, compared to the placebo, saffron was associated with greater improvements in the Depression, Anxiety, and Stress scale – 21 depression score (β: -2.92 points; 95% confidence interval: -5.13, -0.71 points; Cohen’s d = 0.39). 72% of participants in the saffron group achieved a clinically significant change (a reduction of ≥ 7 points) compared to 54.3% of participants in the placebo group (P = 0.010). However, in the other secondary outcomes, there was no evidence of between-group differences. In exploratory analyses across various strata and assumptions, improvements in sleep disturbances (β: -2.72 points; 95% confidence interval: -4.99, -0.46 points; Cohen’s d = 0.44) were identified in a subset of participants with a greater severity of sleep disturbance. There were no serious adverse reactions reported.
The authors concluded that this study, the largest conducted to date on saffron, provides evidence supporting the beneficial effects of 3 mo of saffron supplementation on depressive symptoms in adults. Large placebo responses were evident in this study, which require consideration in future trials.
As mentioned above, the body of evidence suggesting that saffron is effective for a surprisingly wide range of conditions is impressive. I looked with some skepticism at some of these studies and have to say that many are of decent or even good scientific quality.
Could it be that we have in saffron a plant-based treatment that shows real promise?
WATCH THIS SPACE!
As I am not an avid reader of the UK honours lists, I totally missed the fact that Robin Daly has been awarded an MBE (Member of the Order of the British Empire) in the 2025 New Year Honours list. The honour was for his outstanding contributions to the field of integrative cancer care as the founder of the charity, “Yes to Life”. The “Yes to Life” website reported the event as follows:
We are thrilled to announce that our Chairman and Founder, Robin Daly, has been awarded an MBE in recognition of his outstanding contributions to the field of integrative cancer care and his tireless work through Yes to Life. This prestigious honour celebrates Robin’s unwavering dedication to supporting those affected by cancer and promoting holistic approaches to well-being. Congratulations, Robin, on this well-deserved accolade! …
On this blog, we have encountered “Yes to Life” before, e.g.:
- The ‘Yes to Life Show’ is outright dangerous, if you ask me
- Uncharitable charities? The example of ‘YES TO LIFE’
I had again a good look at what “Yes to Life” is currently offering and am glad to report that they clearly cleaned up their act. The charity used to promote outright dangerous quackery to desperate cancer patients. Today they still do this but they do it less overtly, e.g.:
- “Whether you’re seeking improved mental clarity, glowing skin, weight loss, detoxification, or support in battling diseases like cancer, juicing offers a customisable approach to achieving your wellness goals. In this comprehensive guide, we’ll explore how to adapt your juicing routine to address specific health needs, from overall well-being to targeted concerns like skin health, mental well-being, weight loss, detoxification, menopause, heart health and cancer support.”
- “From the moment of diagnosis through treatment and beyond, cancer patients face plenty of challenges that extend far beyond the physical symptoms. Emotional Freedom Techniques (EFT), also known as tapping, have emerged as a promising support offering a gentle yet profound approach to addressing emotional and psychological well-being. At its core, EFT is a modality that combines elements of ancient Chinese acupressure with modern psychology. The technique involves gently tapping on specific acupressure points on the body while focusing on and verbalizing emotional issues, negative thoughts, or physical symptoms. By stimulating these energy meridian points and addressing emotional blockages, EFT aims to restore balance to the body’s energy system and promote healing on a holistic level.”
- “Turmeric, often referred to as the “golden spice,” contains curcumin, a compound with powerful anti-inflammatory and antioxidant properties. Curcumin has been linked to enhanced immune function and may help the body defend against infections. You can incorporate turmeric into your diet by adding it to curries, soups, or even warm turmeric milk for a comforting and immune-boosting treat.”
- “Stress, anxiety, and emotional distress as well as physical pain and discomfort may be present along the entire cancer care pathway. These factors may impact treatment outcomes and recovery time. Most importantly, they present a significant burden of suffering to those affected by cancer and their loved ones. EFT is an effective, efficient management tool that can meet these needs and can be self- administered as well as used in a therapeutic relationship. The physical and emotional need for support can vary timewise along the cancer pathway and sometimes surprisingly patients can have significant mental and emotional needs as they recover, so well beyond their treatment phase (see the accompanying graph). Meeting these needs can contribute to long term well-being.”
- “The slightly strange sounding ‘Essiac’ tea is, in fact, simply a reversal of the surname of the woman who made it famous. In 1922, a young Canadian nurse, Rene Caisse, was given certain herbs by an old woman who had cured herself of breast cancer and had been handed down the recipe by the Ojibawa Native Americans who had used it for generations.”
Are we sure that the promotion of a whole lot of caner quackery merits a gong?
No!
Oddly, as I was writing this, I came across this on social media:
Ken Loach refused one of Betty’s gongs, in 1977, saying: ‘I turned down the OBE because its not a club you want to join when you look at the villains who’ve got it. It’s all the things I think are despicable: patronage, deferring to the monarchy and the name of the British Empire, which is a monument of exploitation and conquest’.
Perhaps we should add QUACKERY to Ken Loach’s list?
‘Anti-nutrients‘ (ANs) are compounds found primarily in plant-based foods that interfere with the absorption and utilization of certain nutrients. Essentially, thet consitute a plant’s defense mechanism against predators. ANs include a range of compounds.
- Phytates (Phytic Acid): Found in whole grains, seeds, nuts, and legumes. They can bind to minerals like iron, zinc, magnesium calcium etc and reduce their absorption.
- Lectins: Found in legumes and grains, they can interfere with nutrient absorption and cause digestive discomfort.
- Oxalates (Oxalic Acid): Present in leafy greens, they bind to calcium and other minerals, making them less available for absorption.
- Tannins: Found in tea, coffee, and some legumes, they can inhibit the absorption of iron and interfere with the digestion of protein.
- Goitrogens (Glucosinolates): Found in cruciferous vegetables (e.g. broccoli, cabbage, and kale), they can interfere with iodine uptake by the thyroid gland.
For avoiding problems, it is relevant to remember that most ANs are reduced or deactivated by normal food preparation methods like soaking, sprouting, boiling, and fermentation.
So, why the hooha?
Diets like keto, paleo, and carnivore eliminate or restrict whole food groups (like grains and legumes) that are high in ANs. Proponents of these diets hype the topic of anti-nutrients to justify excluding these plant foods. In the wellness sphere, the negative aspects of ANs tend to be exaggerated, leading to fear-mongering about consuming perfectly healthy foods.
Several of the compounds classified as ANs (e.g. phytates and tannins) have, in fact, significant health benefits. Reasonable experts acknowledge that ANs exist and can inhibit nutrient absorption. However, they stress that for the vast majority of people consuming a varied and well-prepared diet, the negative effects are negligible.
In summary, for most people consuming a balanced diet, ANs should not be a major concern. The overall benefits of eating whole, plant-based foods far outweigh the potential negative effects of ANs.
Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of the herbal extract VER-01 in CLBP.
It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure.
The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal.
The authors of this well-designed trial concluded that this phase 3 study provides robust evidence supporting the efficacy and safety of VER-01 in the treatment of CLBP. These findings highlight the importance of further research with VER-01 in other chronic pain conditions and suggest that VER-01 could play an important role in modern pain management.
VER-01 was developed by the German biopharmaceutical company Vertanical. It is a standardized full-spectrum extract from a specific Cannabis sativa strain (DKJ127 L). This means it contains a defined mix of the plant’s compounds, including cannabinoids (such as low levels of THC—tetrahydrocannabinol—and trace amounts of CBD and cannabigerol), terpenes, and other bioactive compounds like beta-caryophyllene and alpha-bisabolol. It is designed to harness the synergistic “entourage effect” of these compounds.
The extract has also recently been shown to be superior to opioids. An RCT concluded that VER-01 demonstrated superiority over opioids in treating CLBP, both in terms of efficacy and gastrointestinal tolerability.
PS
Given the option of either having spinal manipulation (or any other form of unproven so-called alternative medicine) or a safe and standardised cannabis extract, I certainly know what I would choose!
PPS
Vertanical has submitted marketing applications for approval in several European countries (where it is expected to be sold under the brand name Exilby if approved). The company is also preparing for a late-stage trial in the US to support a subsequent filing with the FDA. If approved, VER-01 would be the first full-spectrum cannabis extract authorized specifically for chronic low back pain and potentially a new class of medicine for chronic pain management.
While still Prince of Wales, Charles was once asked if his campaigning for so-called alternative medicine (SCAM) would continue once he became king. His answer was unusually clear: “No, it won’t. I’m not that stupid.” Now that he has been king for three years, it seems reasonable to review his activities in SCAM during this period. Here is a brief summary:
- In 2023, Charles appointed Dr. Michael Dixon (yes, you may have met him several times before, e.g. here, here, or here) as the Head of the Royal Medical Household.
- Charles retained his role as Royal Patron of the Faculty of Homeopathy, an organisation dedicated to supporting registered health professionals who practice homeopathy.
- Charles and Camilla have continued their practice of visiting the Soukya International Holistic Health Centre in India, which employs treatments like Ayurveda, homeopathy, and yoga.
- In 2023, in THE TIMES reported that Charles has decided to use one particularly implausible form of SCAM, reflexology, for helping women who have difficulties getting pregnant.
- One of Charles’ charities had to return £110,000 to the Indian government in 2023. The funds had been earmarked for an NHS SCAM clinic championed by Charles. Yet, the clinic never materialised. The ‘Ayurvedic Centres of Excellence’ was to open in 2018 in London. Funding was to come from the Indian government and from private donors. At the time, Dr Michael Dixon commented enthusiastically: “This is going to be the first Ayurvedic centre of excellence in the UK. We will be providing, on the NHS, patients with yoga, with demonstrations and education on healthy eating, Ayurvedic diets, and massage including reflexology and Indian head massage. And all this will be subject to a research project led by Westminster University, to find out whether the English population will take to yoga and these sorts of treatments. Whether they will be helped by it and finally whether it will reduce the call on NHS resources leading to less GP consultations, hospital admissions and operations.”
- In 2024, Charles has personally honoured Dr Michael Dixon, head of the Royal Medical Household, by making him a Commander of the Royal Victorian Order (CVO).
While less outspoken on the topic of SCAM since his accession than he was as the Prince of Wales, these published activities (it seems safe to assume that thaere are many more the public does not learn about) clearly are a royal endorsement for SCAM. In other words, when Charles predicted “I’m not that stupid”, he may not have been entirely correct.
